{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-288019","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.795479+00:00","generated_at":"2026-06-07T18:51:57.622138+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"BioAtla holds KOL event on BA3011 Phase 2 NSCLC data; no specific results given","bullets":["KOL event on Dec 4 featured Dr. Carl M. Gay (MD Anderson) discussing BA3011 (CAB-AXL-ADC) Phase 2 data in refractory NSCLC.","Select slides from the presentation filed as Exhibit 99.1; no detailed efficacy or safety numbers provided in the filing.","Company reiterates forward-looking statements; no guidance or material changes announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-288019","json":"https://secwatch.observer/filing/0001193125-23-288019.json","markdown":"https://secwatch.observer/filing/0001193125-23-288019.md","text":"https://secwatch.observer/filing/0001193125-23-288019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312523288019/0001193125-23-288019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312523288019/d630019d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:51:57.622138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}